v3.26.1
Segment Reporting - Summary of Financial Information for Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
External costs by program    
Research and development $ 1,545 $ 12,180
General and administrative 5,208 5,449
Total operating expenses 7,365 17,629
Loss from operations (7,365) (17,629)
Interest income 609 1,420
Net loss (5,756) (16,556)
Reportable Segment    
Internal costs    
Total salary / benefits 1,896 5,394
External costs by program    
General and administrative 3,943 2,430
Other segment items 819 3,030
Total operating expenses 7,365 17,629
Loss from operations (7,365) (17,629)
Interest income 609 1,420
Gain on sale of nonfinancial asset 1,000 0
Interest expense 0 (347)
Net loss (5,756) (16,556)
Reportable Segment | Zetomipzomib    
External costs by program    
Research and development 698 6,091
Reportable Segment | KZR-261    
External costs by program    
Research and development $ 9 $ 684